Cases & Deals

Sofinnova acts as lead investor in ProQR Therapeutics cross over investment round

Clients Sofinnova Partners

Jones Day advised Sofinnova Partners, as lead investor, in the €42 million (US$58 million) Series A Convertible Preferred Stock private placement by ProQR Therapeutics B.V., a biotech company focused on the development of drugs to treat genetic disorders. The financing round included a number of U.S.-based cross over investors. The investment round was ahead of the IPO of ProQR Therapeutics on NASDAQ.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.